Cellino’s Post

#GeneTherapy and #GenomeEditing may feel futuristic and out-of-reach, but it's here. Now, how do we make it accessible to the average person? Some ideas from Peter Marks, Director of #FDA CBER; David Barrett, CEO of American Society of Gene & Cell Therapy; and Nicole Guadelli of GV (Google Ventures): - Explore non-bespoke therapies - Get #RareDisease patients access to technologies and drugs in late stage development - Further explore the potential of #mRNA and #GuideRNA for #GeneEditing - Improve education about the complexities of these therapies, both within the #pharma industry and outside of it - Collaborate and share knowledge about what works and how #NORDSummit #Biotech #Biotechology #CRISPR #DrugDevelopment

“As the advanced therapy sector approaches a critical juncture in its growth, the industry’s ability to navigate these challenges will define its trajectory and potential to revolutionize treatment paradigms.” – Deloitte’s 2024 Advanced Therapy Industry Report Examining the current landscape of cell and gene therapy, with input from 376 respondents across the ecosystem, Deloitte's report identifies both challenges and opportunities across research, development, manufacturing, commercialization and patient access. Key insights from the report include: ⚙️Over 40% of industry leaders are unsure about meeting the future demand for advanced therapies ⚙️Nearly 90% of therapy developers are now collaborating with external manufacturers to accelerate the path to market ⚙️Payer and reimbursement issues remain a top concern for the commercialization of advanced therapies We’ve summarized the key takeaways ⬇️ Download the full report: https://lnkd.in/eDFPAutA #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Meet the team- Listen to adthera board member & Delin Ventures partner, Jonathan Hay discuss his views of adthera's cell therapy focused CDMO and how it fits within Delin Ventures' Cell & Gene therapy investment strategy. Connect with us to book a visit and see for yourself info@adthera.bio | adthera.bio #cdmo #regenerativemedicine #digitalfirst #celltherapy #immunotherapy #innovation #processdevelopment #continousimprovement #gmp #clinicaltrials #atmp #advancedtherapies #personalizedmedicine #gxp #optimization #automation #bestinclass #rightfirsttime #celltherapymanufacturing #innovation #digital #partnerships #collaboration #vc #investment #venturecapital

"It’s less of a business partnership and more of a mission partnership."    We're thrilled to collaborate with visionary leaders like 🎗️Ohad Karnieli Karnieli from Adva Biotechnology. In this video, Ohad shares what excites him most about our partnership: advancing Cell and Gene Therapy through innovation and teamwork.   By combining Adva’s X3® cell manufacturing platform with Xiogenix’s ARES™ X20 fill-and-finish system, we’re delivering a more flexible, end-to-end solution that simplifies processes, enhances precision, and brings life-saving therapies closer to patients.   At Xiogenix, we’re committed to driving innovation through collaboration and shaping the future of Cell and Gene Therapy. Learn more about our mission and technology at www.xiogenix.com   Allie Schroeder, Sami Reimer, Rachel Bahr, Jerry Jendusa 🎗 Ofra Toledo, #CellAndGeneTherapy #InnovationInMedicine #Collaboration #Xiogenix #AdvaBiotechnology #MaximizingLife

🔬 Featured Session: Cell & Gene Therapy Manufacturing – A Look at Supply Chains, Treatment Centers, and Patient Slots 🧬 https://ow.ly/6RgY50TKYmH Join us on Wednesday, November 20 for an in-depth discussion on the challenges and innovations in cell and gene therapy manufacturing. Since the launch of CAR-T therapies like Novartis' Kymriah, production limitations have been a key hurdle. This panel will dive into how developers are managing supply chain issues, ensuring patient access, and scaling capacity to meet growing demand. Whether you're navigating CAR-Ts or the latest gene therapies, this session will provide the insights you need to overcome production challenges and drive success. ➡️Don't miss out! Register now: https://ow.ly/6RgY50TKYmH Thank you to our Moderator and Speakers: - Fraiser Kansteiner from Fierce Pharma - Arturo Araya from Cellares - Milos Miljkovic from Cartesian Therapeutics - Alina Monakhova from Adaptimmune - Vaishali Shukla, PhD from Kite Pharma #CellandGene #Biotech #HealthcareInnovation #CAR-T #SupplyChain #GeneTherapy #FierceCellAndGene

New Year, BIG News! 📢 PBS Biotech secures $17 Million in Growth Capital to Accelerate Delivery of Next Generation Cell and Regenerative Therapies. We are committed to scaling up our business to meet the growing demands of the cell and gene therapy industry to bring life-saving treatments faster with the support of our investors, Avego and BroadOak Capital Partners. 📽️ DISCLAIMER: The video below is strictly for entertainment purposes and does not accurately represent mixing in the vertical-wheel bioreactor. For more questions, please feel free to contact us! 👉 Full press release available to read here: https://bit.ly/3Pq8csA

Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3KbQEOm While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3KbQEOm

What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare

Are you working within cell and gene therapy development? Check out the event from Technology Networks airing Nov 13th, including Ryan Nai's presentation on #plasmid and double-stranded #DNA analyses using the latest kit from #SCIEX, streamlining purity determination and size estimation. 💥 #mRNA #vaccines #SCIEX #CE #capillaryelectrophoresis